Dec 14, 2016 Cellectar Biosciences Announces USPTO Grants Patent Allowances for Radiotherapeutic PDCs for A Variety of Solid Tumor Types Learn More
Dec 12, 2016 Cellectar Biosciences Announces USPTO Grants Patent for Paclitaxel PDC; Provides Additional Patent Protection for Select Solid Tumors Through 2035 Learn More
Dec 6, 2016 Cellectar Biosciences Presents Poster at the 58th Annual Meeting of the American Society of Hematology Learn More
Dec 1, 2016 Cellectar Biosciences Announces Results From the First Two Cohorts of Its CLR 131 Phase 1 Trial: Demonstrates Excellent Efficacy, Overall Survival Benefit, and Progression Free Survival Similar to or Better than Recently Approved Therapies Learn More